Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.
https://www.fiercepharma.com/pharma/biontech-eu12-4b-potential-2021-covid-vaccine-sales-aspires-to-global-immunotherapy
These include mRNA vaccine candidates BNT111 and BNT113. The former candidate will be paired with Regeneron and Sanofi’s Libtayo for PD-1-pretreated melanoma. And the latter vaccine will be combined with Merck’s Keytruda in HPV16-positive head and neck squamous cell carcinoma.
Nearly one year ago, AZ agreed to pay $1 billion upfront over two years for ex-Japan rights to the drug, which works as an ADC that targets tumor-associated protein TROP2, plus another $5 billion in milestones.
https://www.fiercebiotech.com/biotech/daiichi-sankyo-astrazeneca-s-5b-enhertu-follow-up-shows-early-signs-success-breast-cancer
https://twitter.com/BertrandBio/status/1390572428355637253?s=20
I wonder will Biontech fancy buying SCLP at some stage?
Good aul Diane
https://youtu.be/EI33riFzzk8
Carl Quintanilla
@carlquintanilla
·
1h
Pfizer CEO
@AlbertBourla
, on IP waivers:
“truly believe that makes zero sense, not to mention about the disincentives that will create the whole biotech industry, if waiving the patents, What does it mean in the next pandemic?” $PFE
I very much doubt that it will happen. Biden is a balloon.
Pharma industry fears Biden’s patent move sets dangerous precedent
https://www.ft.com/content/f54bf71b-87be-4290-9c95-4d110eec7a90
Brad Loncar
@bradloncar
“Intellectual property is the lifeblood of biotech, it’s like oxygen to our industry,” said Brad Loncar, a biotech investor. “If you take it away, you don’t have a biotech sector.”
Possibly the Chinese vaccine was the reason Crumbs?
In April, China's top disease control official said the efficacy of the country's Covid vaccines was low, although he later insisted his comments had been misinterpreted.
Researchers in Brazil have put the efficacy of another Chinese-made vaccine, the Sinovac vaccine, at 50.4%.
https://www.cobrabio.com/plasmid-dna
Gene Therapy Net
@genetherapynet
·
1h
4x Capacity to Fulfil your HQ Plasmid Needs
#Cobra is undergoing a multi-phase augmentation of its pDNA services. The HQ manufacturing service provides a rapid delivery time for the clinical manufacture of immuno-oncology therapies. https://cobrabio.com/plasmid-dna
gooosed5 May '21 - 10:43 - 39038 of 39040
0 1 0
Https://twitter.com/UniofNottingham/status/1389867569553756160?s=19
Uni of Nottingham #WeAreUoN
@UniofNottingham
·
2h
We are delighted to appoint
@DrTedros
@WHO
Director General as Honorary Professor
@UniofNottingham
@nottmhospitals
. The appointment is part of the 50th and 30th anniversaries of our world-leading Schools of
.
As he said, with 100 different CVs, some may appear which are much more deadly than cv 19. If Scancell can make Covidity work it would be fantastic .
“We need to move ultimately to producing coronavirus vaccines which are broadly protective.”
Our CEO,
@DrRHatchett
, CEPI
Sanofi bought them for 1 billion. I would like to think that Scancell should be worth that relatively soon.
https://www.kymab.com/pipeline/
Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L
upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones.
https://www.globenewswire.com/news-release/2021/01/11/2155914/0/en/Sanofi-to-acquire-Kymab-adding-KY1005-to-its-pipeline-a-human-monoclonal-antibody-targeting-key-immune-system-regulator-OX40L.html
https://twitter.com/reuterspictures/status/1388216584842452999?s=20
A report from GlobalData, Melanoma – Global Drug Forecast and Market Analysis to 2029, has predicted the melanoma industry will grow from $5.59bn in 2019 to $7.42bn in 2029 across the eight major markets at a compound annual growth rate of 2.9%.
“The problem of how to treat patients who progress on immune checkpoint inhibitors is a tough one. Around 50% of patients on this therapy will progress, and while BRAF-positive patients have the option of receiving targeted BRAF/MEK inhibitors, there are no good options here for BRAF wild-type patients.
http://www.pharmafile.com/news/577057/melanoma-market-reach-74bn-2029
https://www.scancell.co.uk/asco-update-on-phase-12-clinical-trial-of-scib1-in-stage-iiiiv-melanoma
emptyend29 Apr '21 - 09:49 - 38915 of 38915
0 1 0
Reminder.....this was one of the last (re)tweets from Scancell's Twitter account. The last tweet was on 12th March.....
https://twitter.com/cepivaccines/status/1369404403787177999?s=21
Either the person who operated the Twitter account has been run over by a bus - or this is a self-imposed silence.....presumably to avoid compromising discussion with CEPI and/or others....
Not a time for impatience, IMO.....
emptyend29 Apr '21 - 09:49 - 38915 of 38915
0 1 0
Reminder.....this was one of the last (re)tweets from Scancell's Twitter account. The last tweet was on 12th March.....
https://twitter.com/cepivaccines/status/1369404403787177999?s=21
Either the person who operated the Twitter account has been run over by a bus - or this is a self-imposed silence.....presumably to avoid compromising discussion with CEPI and/or others....
Not a time for impatience, IMO.....
STATUS
Recruiting
END DATE
Sep 30, 2023
PARTICIPANTS NEEDED
25
SPONSOR
Scancell Ltd
Updated on 24 January 2021
Summary
Show definitions
The purpose of this study is to find out if a new treatment called SCIB1 can be used safely when added to pembrolizumab (Keytruda), a standard therapy approved for the treatment of advanced melanoma (skin cancer). Pembrolizumab is an antibody treatment for cancer.
The study will also look to see if SCIB1 can increase the likelihood that melanoma patients will respond to pembrolizumab, and also if SCIB1 can help to make those responses last longer. Pembrolizumab is considered a standard treatment for patients with advanced melanoma. SCIB1 is considered experimental. SCIB1 has been given to melanoma patients in an earlier study. It was generally well tolerated, and researchers saw some signs that it may help to stimulate the immune system, which is a way in which the body can fight the cancer.
This study is expected to enrol approximately 25 melanoma patients worldwide.
Description
This is an open label, single arm Phase 2 study to determine the safety and tolerability of SCIB1 administered to patients with advanced melanoma using an electroporation device (the TDS-IM v2.0 device) when added to pembrolizumab (Keytruda), a standard treatment already approved for the treatment of advanced melanoma.
The plan for this research study is for SCIB1 to be given for up to 2 years, in combination with pembrolizumab according to the current label.
After receiving the first dose of SCIB1, the patient will then receive SCIB1 3 times, 3 weeks apart, then once 6 weeks later, and after that once every 12 weeks until the treatment is stopped.
Pembrolizumab will be given by an injection into the patient's vein once every 3 weeks. The injection, known as an infusion, usually takes about 30 minutes to complete.
Every time the patient has a SCIB1 infusion, they will also receive pembrolizumab. Additionally, there will also be some days when the patient will receive pembrolizumab alone.
On each occasion, SCIB1 will be given by two injections into a muscle in a different limb, e.g. one into the upper arm and the other into the thigh. Instead of a normal needle and syringe, a small, hand-held device TDS-IM v2.0 will be used to inject SCIB1 into the muscles. The site of SCIB1 administration will alternate on each occasion.
The injection device is designed to increase the amount of SCIB1 that is delivered to the muscle cells. The liquid containing SCIB1 will be delivered through the injection needle. Immediately after the injection, the device will give a very short electrical impulse to the muscle through the four thin wires at the site of the injection. The impulse will last for less than one tenth of a second. A short video will be shown to the patient before the first injection is given to show the patient what will happen.
Before treatment starts and after consent has been given, all patients w
If Scancell have joy with covid then maybe they can have a go at a universal influenza jab.
Matrix protein 1 (M1) is a well-conserved internal protein. ... Influenza
https://academic.oup.com/jid/article/222/5/807/5628940
Yes Ivy, Imagine if we get a CV that spreads like this Bat Flu but is as deadly as Mers with a 35.5% mortality rate. That is one reason why Scancell`s work could be vital.
“We didn’t learn after SARS, MERS, HIV, swine flu—but maybe this time we will.”
In just the past 18 years, three coronaviruses have caused devastating human diseases (SARS, MERS, and COVID-19). “It’s not a question of if but when another pandemic coronavirus emerges,” Martinez says.
Bjorkman shares this certainty. “This isn’t going to be the last one,” she says. “We’re going to have SARS-CoV-3 and SARS-CoV-4. Everyone said this before the current pandemic. Most of the world ignored them. To do so again would really be burying your head in the sand.”